Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].

证券日报网讯 2月10日，艾德生物发布公告称，公司股东厦门科英投资合伙企业（有限合伙）于2026年 2月3日至2月9日通过集中竞价及大宗交易合计减持4775100股，占总股本1.22%，减持计划已完成，减 持后其持股比例由4.08%降至2.86%。 （文章来源：证券日报） ...

证券代码：300685 证券简称：艾德生物 公告编号：2026-004 厦门艾德生物医药科技股份有限公司 关于特定股东减持计划完成的公告 股东厦门科英投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 厦门艾德生物医药科技股份有限公司（以下简称"艾德生物"或"公司"） 于2026年1月28日披露了《关于特定股东减持计划的预披露公告》（公告编号： 2026-002）。持公司股份15,940,946股的股东厦门科英投资合伙企业（有限合伙） （以下简称"厦门科英"）计划在本减持计划公告之日起三个交易日后的三个月 内以大宗交易和集中竞价的方式减持公司股份，减持数量不超过4,775,100股。 厦门科英出具的《股份减持情况告知函》。 特此公告。 二、股东本次减持前后持股情况 | 股东名称 | 股份性质 | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | | | 持股数量 | 占总股本比 | 持股数量 | 占总股 ...

证券日报网讯2月2日，艾德生物（300685）发布公告称，截至2026年1月31日，公司通过回购专用证券 账户以集中竞价交易方式实施回购股份696，400股，占公司目前总股本的0.18%，回购股份的最高成交 价为22.16元/股，最低成交价为20.50元/股，支付的总金额为14，990，827.10元(不含交易费用)。 ...

格隆汇2月2日丨艾德生物(300685.SZ)公布，截止2026年1月31日，公司通过回购专用证券账户以集中竞 价交易方式实施回购股份696,400股，占公司目前总股本的0.18%，回购股份的最高成交价为22.16元/ 股，最低成交价为20.50元/股，支付的总金额为14,990,827.10元（不含交易费用）。本次回购符合公司 既定的回购股份方案及相关法律法规的要求。 ...

每经AI快讯，艾德生物2月2日晚间发布公告称，截至2026年1月31日，公司通过回购专用证券账户以集 中竞价交易方式实施回购股份约70万股，占公司目前总股本的0.18%，回购股份的最高成交价为22.16 元/股，最低成交价为20.5元/股，支付的总金额约为1499万元。 每经头条（nbdtoutiao）——曾卖劳斯莱斯、保时捷等豪车，汽车销售巨头宝利德如今破产清算：杭州 总部已人去楼空，义乌子公司贴上了封条 （记者 王晓波） ...

厦门艾德生物医药科技股份有限公司 关于回购公司股份的进展公告 证券代码：300685 证券简称：艾德生物 公告编号：2026-003 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于2025年11月10日召开2025年第一次临时股东大会，审议通过了《关于以集中竞 价交易方式回购公司股份的议案》。公司使用自有资金和/或自筹资金，以集中 竞价方式回购股份用于注销并减少公司注册资本；回购资金总额为不低于人民币 10,000万元且不超过人民币20,000万元，具体回购资金金额以回购实施完成时实 际回购的金额为准；回购股份的实施期限为自公司股东大会审议通过本次回购方 案之日起12个月内。具体内容详见公司于2025年11月18日刊登在巨潮资讯网的 《回购报告书》。 根据《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》等相关规 定，现将公司回购股份进展的有关情况公告如下： 一、截止上月末的回购进展情况 截止 2026 年 1 月 31 日，公司通过回购专用证券账户以集中竞价交易方式实 施回购股份 ...

Group 1 - Zhongyuan Expressway (600020) expects a net profit of approximately 612 million yuan for 2025, a decrease of about 30% year-on-year [1] - Bomin Electronics (603936) anticipates a net profit of 15 million to 22 million yuan for 2025, achieving a turnaround from loss to profit compared to the previous year [2] - Fangda Special Steel (600507) forecasts a net profit of 835 million to 998 million yuan for 2025, an increase of 236.9% to 302.67% year-on-year [3] Group 2 - Jiadu Technology (600728) expects a net profit of 160 million to 200 million yuan for 2025, recovering from a loss of 115 million yuan in the previous year [4] - Changyang Technology (688299) predicts a net loss of 116 million to 168 million yuan for 2025 [5] - Zhongzi Technology (688737) anticipates a net loss of 45.24 million to 67.86 million yuan for 2025 [6] Group 3 - Two-sided Needle (600249) expects a net profit of 5 million to 10 million yuan for 2025, a decline of 87.67% to 93.83% year-on-year [7] - Sanrenxing (605168) forecasts a net profit of 181 million to 209 million yuan for 2025, an increase of 46.79% to 69.5% year-on-year [8] - Shubeide (300322) anticipates a net profit of 60 million to 70 million yuan for 2025, recovering from a loss of 64.46 million yuan in the previous year [9] Group 4 - Maoye Commercial (600828) expects a net loss of 201 million to 242 million yuan for 2025 [10] - Hongsheng Huayuan (601096) forecasts a net profit of 348 million to 400 million yuan for 2025, an increase of 51.22% to 73.82% year-on-year [11] - Huafeng Technology (688629) anticipates a net profit of 338 million to 388 million yuan for 2025, achieving a turnaround from loss to profit [12] Group 5 - Aerospace Rainbow (002389) expects a net profit of 25 million to 31 million yuan for 2025, a decrease of 64.84% to 71.65% year-on-year [14] - Shangong Shenbei (600843) predicts a net loss of 120 million to 150 million yuan for 2025, compared to a loss of 244 million yuan in the previous year [15] - Chaoxun Communication (603322) anticipates a net profit of 36 million to 54 million yuan for 2025, achieving a turnaround from loss to profit [16] Group 6 - Guannong Co. (600251) expects a net profit of 330 million to 340 million yuan for 2025, an increase of 61.29% to 66.18% year-on-year [17] - Shandong Steel (600022) forecasts a net profit of around 100 million yuan for 2025, recovering from a loss of 2.891 billion yuan in the previous year [18] - Baili Technology (603959) anticipates a net loss of 140 million to 200 million yuan for 2025 [19] Group 7 - Electric Power Investment Hydropower (600292) expects a net profit of approximately 517 million yuan for 2025, a year-on-year increase of about 1337% [20] - Aibulu (301259) forecasts a net profit of 26 million to 33.8 million yuan for 2025, recovering from a loss of 30.84 million yuan in the previous year [21] - Yipin Hong (300723) announced that its subsidiary received approval for clinical trials of a new drug [22] Group 8 - Meixin Sheng (688458) plans to acquire 100% equity of Xinyan Micro for 160 million yuan [23][24] - Lanshi Heavy Industry (603169) expects a net loss of 370 million to 440 million yuan for 2025, transitioning from profit to loss [25] - Hongyang (000525) anticipates a net loss of 260 million to 390 million yuan for 2025, compared to a profit of 388 million yuan in the previous year [26] Group 9 - Tianzhihang (688277) predicts a net loss of 165 million to 198 million yuan for 2025, with losses expected to widen by 36.22% to 63.46% compared to the previous year [27] - Tongda Co. (002560) announced plans for a major shareholder to reduce holdings by no more than 1% [28] - *ST Chengchang (001270) expects a net profit of 95 million to 124 million yuan for 2025, recovering from a loss of 31.12 million yuan in the previous year [29] Group 10 - Yirui Technology (688301) reported a net profit of 661 million yuan for 2025, a year-on-year increase of 42.15% [30] - Hualitai (001217) anticipates a net loss of 28 million to 38 million yuan for 2025, transitioning from profit to loss [31] - Yunjiji Group (001288) expects a net profit of 220 million to 252 million yuan for 2025, a year-on-year increase of 40% to 60% [32] Group 11 - Heertai (002402) forecasts a net profit of 638 million to 729 million yuan for 2025, an increase of 75% to 100% year-on-year [33] - Shenhao Technology (300853) anticipates a net loss of 185 million to 220 million yuan for 2025, compared to a loss of 238 million yuan in the previous year [34] - Zhongyan Dadi (003001) expects a net profit of 10 million to 15 million yuan for 2025, a decline of 75.97% to 83.98% year-on-year [35] Group 12 - Landai Technology (002765) forecasts a net profit of 180 million to 200 million yuan for 2025, a year-on-year increase of 44.83% to 60.93%, with a non-recurring profit of 140 million to 160 million yuan, an increase of 113.1% to 143.54% [37] - Yingfeite (300582) plans to raise product prices by 5% to 15% starting March 1, 2026, due to rising raw material costs [38] - Lanzhou Bank (001227) plans to distribute 285 million yuan in cash dividends for the 2025 interim profit distribution [39] Group 13 - Wancheng Group (300972) announced plans for shareholders to reduce holdings by no more than 1.27% [40] - *ST Huarong (600421) expects to turn a profit in 2025, with a projected net profit of 6.5 million to 8 million yuan [41] - Jiaheng Home (300955) anticipates a net loss of 29 million to 39 million yuan for 2025, compared to a loss of 23.69 million yuan in the previous year [42] Group 14 - Aide Biology (300685) announced plans for a major shareholder to reduce holdings by no more than 1.22% [43] - Haixia Innovation (300300) expects a net profit of 100 million to 150 million yuan for 2025, a year-on-year increase of 1660.56% to 2540.85% [44]

Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their holdings, indicating potential shifts in investor sentiment and market dynamics [1]. Shareholder Reductions - **Wancheng Group**: Shareholders Peng Dejian and his spouse Fan Hongjuan plan to reduce their holdings by up to 1.2 million shares [1]. - **Tianyang Technology**: Chairman and General Manager Ouyang Jianping intends to reduce his stake by no more than 3% [1]. - **Sudavige**: Shareholder Yu Zhangxing plans to reduce his holdings by up to 1.99% [1]. - **Aide Biology**: Shareholder Xiamen Keying intends to reduce holdings by up to 1.22% [1]. - **Kanshe Shares**: Multiple shareholders plan to collectively reduce their holdings by no more than 2.59% [1]. - **Bozhong Precision**: Shareholder Xinke Hongchuang plans to reduce holdings by up to 4.4665 million shares [1]. - **Zhonggang Luonai**: Shareholder Guo Xin Shuangbai Yihua plans to reduce holdings by 3.3065 million shares [1]. - **Matrix Technology**: Director and senior manager Cui Ling plans to reduce holdings by up to 300,000 shares [1]. - **Hongchang Technology**: Shareholder Jinhua Honghe plans to reduce holdings by no more than 0.33% [1]. - **Meixin Sheng**: Shareholder WI Harper Fund VII plans to reduce holdings by 1% [1]. Other Notable Information - **ST Xinchao**: The company’s stock may face delisting [1]. - **Changjiang Investment**: The stock may be subject to delisting risk warnings [1].

Core Viewpoint - On January 28, no A-share listed companies disclosed any increase in shareholding, while nine companies announced share reductions, indicating a trend of shareholder divestment in the market [1]. Group 1: Share Reduction Details - Tongda Co., Ltd. plans to reduce its shareholding by no more than 1.00% [2] - Hongqi Chain's shareholder Yonghui Supermarket has reduced its stake by 0.79% [2] - Wancheng Group's shareholders intend to collectively reduce their holdings by no more than 1.27% [2] - Hongchang Technology's shareholders plan to reduce their holdings by no more than 0.33% [2] - Tianyang Technology's controlling shareholder Ouyang Jianping intends to reduce his stake by no more than 3% [2] - Aide Biology's shareholder Xiamen Keying plans to reduce its holdings by no more than 1.22% [2] - Juzitech's director and executive Cui Cen intends to reduce his stake by no more than 0.11% [2] - Bozhong Precision's shareholder Xinke Chuang plans to reduce its holdings by no more than 1% [2] - Tianyang's controlling shareholder Guolian Group intends to reduce its stake by no more than 1% [2]